Applied DNA Sciences, Inc. (APDN): Debts to Book Capitalization

Reliable logistics routes guarantee the uninterrupted shipment of synthetic components, while the unique LinearDNA platform provides Applied DNA Sciences (APDN) with significant pricing power in the biosecurity sector. The trajectory of the company's financial leverage on this GURU.Markets chart contains the value 0.05, which determines the extent to which assets cover debts. The business relies on diversification between medicine and IT, creating high-precision tests and protecting textile production from counterfeiting.

This indicator determines the degree of financial leverage through the ratio of total liabilities to the company's equity. An increase in this metric signals bankruptcy risk, while a decrease confirms the stability of the balance sheet structure. By analyzing the ratio of total liabilities to book capitalization on GURU.Markets, an investor can see the actual level of debt load. For Applied DNA Sciences (APDN), this is critical while the effect from LineaRx and DNA components remains moderate. Monitoring this indicator allows for an assessment of the issuer's viability prior to the realization of major therapeutic contracts.